Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gerardo Gamez

Neurology Fort Myers, FL Medical Doctor

NPI 1245240829 CMS profile 101175

12670 Whitehall Dr, Fort Myers, FL 33907

Open in the dashboard

General payments

$24,467

930 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gerardo Gamez of Fort Myers, FL is reported in the CMS Open Payments database as having received $24,467 across 930 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,224 183
2024 General $4,291 167
2023 General $4,546 151
2022 General $3,643 138
2021 General $3,107 115
2020 General $1,366 73
2019 General $2,290 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gerardo Gamez
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Gerardo Gamez were reported at $5,224. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Gerardo Gamez Neurology median Middle half National median
2019 $2,290 $474 $118–$2,177 $163
2020 $1,366 $367 $82–$2,309 $114
2021 $3,107 $438 $104–$2,547 $132
2022 $3,643 $442 $103–$2,388 $149
2023 $4,546 $464 $119–$2,312 $160
2024 $4,291 $468 $119–$2,323 $164
2025 $5,224 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,939 124 payments
  2. EMD Serono, Inc. $1,385 27 payments
  3. UCB, Inc. $1,357 39 payments
  4. Teva Pharmaceuticals USA, Inc. $1,096 35 payments
  5. Amgen Inc. $1,080 47 payments
  6. ACADIA Pharmaceuticals Inc $1,006 50 payments
  7. Genzyme Corporation $985 21 payments
  8. Alexion Pharmaceuticals, Inc. $940 31 payments
  9. Novartis Pharmaceuticals Corporation $781 39 payments
  10. Lundbeck LLC $739 29 payments
  11. Other $12,157 488 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $24,290 920 payments
  2. Education $147 8 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,890 72 payments
  2. QULIPTA $1,308 50 payments
  3. NUPLAZID $638 21 payments
  4. OCREVUS $637 14 payments
  5. ZEPOSIA $615 12 payments
  6. INGREZZA $573 24 payments
  7. Austedo XR $565 16 payments
  8. AIMOVIG $563 30 payments
  9. KESIMPTA $489 23 payments
  10. ULTOMIRIS $485 20 payments
  11. Other $16,603 721 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

3,096

Median for Neurology: 833

Drug cost

$512,999

Median for Neurology: $202,670

Branded share of claims

21.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 26 $236,349
Nuplazid Pimavanserin Tartrate Brand 20 $99,230
Rytary Carbidopa/Levodopa Brand 19 $39,546
Ubrelvy Ubrogepant Brand 15 $17,948
Rivastigmine Generic 87 $14,906
Emgality Pen Galcanezumab-Gnlm Brand 14 $9,830
Memantine Hcl Generic 235 $9,152
Aimovig Autoinjector Erenumab-Aooe Brand 12 $8,557
Carbidopa-Levodopa Er Carbidopa/Levodopa Brand 66 $8,446
Gabapentin Generic 307 $5,969

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$272,097

Of which drugs: $24,970

Medicare patients

1,054

Average age 76

Services billed

8,405

578 women, 476 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 38%
Depression 37%
Diabetes 29%
Chronic kidney disease 27%
COPD 23%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 14 4,400 $21,352
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 23 33 $31

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$380 15 —
ULTOMIRIS
$315 — —
REXULTI
$240 — —
DAXXIFY
$206 — —
ZEPOSIA
$189 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

930 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record